Cargando…

Canakinumab treat-to target strategies increase complete response rate in CAPS

Detalles Bibliográficos
Autores principales:	Kuemmerle-Deschner, J, Hofer, F, Endres, T, Kortus-Goetze, B, Blank, N, Weißbarth-Riedel, E, Schuetz, C, Kallinich, T, Krause, K, Rietschel, C, Horneff, G, Benseler, SM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599896/ http://dx.doi.org/10.1186/1546-0096-13-S1-P173

Ejemplares similares

PW02-041 - Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
por: Kalabus, J, et al.
Publicado: (2015)

Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab
por: Brogan, P, et al.
Publicado: (2015)

PW02-040 - Low-penetrance NLRP3 variants
por: Endres, T, et al.
Publicado: (2013)

PReS-FINAL-2331: Low-penetrance NLRP3 variants
por: Endres, T, et al.
Publicado: (2013)

Unmet psychosocial needs in CAPS
por: Erbis, G, et al.
Publicado: (2015)

Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger
por: Brogan, Paul A., et al.
Publicado: (2019)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report
por: Hansmann, Sandra, et al.
Publicado: (2011)

Abatacept in difficult-to-treat juvenile idiopathic arthritis
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2008)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
por: Bader-Meunier, B, et al.
Publicado: (2011)

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2011)

Determinants of health-related quality of life in children and adults with autoinflammatory diseases
por: Erbis, G, et al.
Publicado: (2015)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

IL-1 inhibition in Muckle-Wells-Syndrome: withdrawal resulting in rapid deterioration of hearing loss
por: Hansmann, S, et al.
Publicado: (2015)

Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative
por: Hansmann, Sandra, et al.
Publicado: (2020)

P02-027 - Quality of life in CAPS treated by Canakinumab
por: Marsaud, C, et al.
Publicado: (2013)

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
por: Kümmerle-Deschner, J, et al.
Publicado: (2008)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

The phagocyte specific protein S100A12 as a novel biomarker in Muckle-Wells-Syndrome before and during therapy with Anakinra and Canakinumab (ACZ885)
por: Wittkowski, H, et al.
Publicado: (2008)

Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry
por: Raab, A., et al.
Publicado: (2021)

Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?
por: Welzel, Tatjana, et al.
Publicado: (2021)

Dynamic knee joint function in children with juvenile idiopathic arthritis (JIA)
por: Hansmann, Sandra, et al.
Publicado: (2015)

Management of Monogenic IL-1 Mediated Autoinflammatory Diseases in Childhood
por: Welzel, Tatjana, et al.
Publicado: (2021)

Colchicine – an effective treatment for children with a clinical diagnosis of autoinflammatory diseases without pathogenic gene variants
por: Welzel, Tatjana, et al.
Publicado: (2021)

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry
por: Walker, Ulrich A, et al.
Publicado: (2021)

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Toker, Ori, et al.
Publicado: (2010)

Colchicine Effectiveness and Safety in Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis
por: Welzel, Tatjana, et al.
Publicado: (2021)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
por: Salugina, Svetlana O, et al.
Publicado: (2014)

Efficacy of canakinumab in biologic-naïve versus previously biologic-exposed SJIA patients: a 12 week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2014)

PW02-037 - The Eurofever cohort of 136 patients with CAPS
por: Levy, R, et al.
Publicado: (2013)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
por: Caorsi, R, et al.
Publicado: (2011)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Evidence based recommendations for diagnosis and treatment of cryopyrin-associated periodic syndromes (CAPS)
por: Haar, Nienke Ter, et al.
Publicado: (2014)

PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2013)

P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized
por: Gautier, A, et al.
Publicado: (2013)

“Daily life of CAPS patients treated with canakinumab (Ilaris(®)) : data from the French observational study - ENVOL Study”
por: Koné-Paut, I, et al.
Publicado: (2015)

Tapering of biological treatment in autoinflammatory diseases: a scoping review
por: Welzel, Tatjana, et al.
Publicado: (2022)

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
por: Koné-Paut, Isabelle, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_lgbtf43pg711hljebah2jg8fom